MedTrace Logo

AZD6738 Plus Durvalumab in Biliary Tract Cancer

NCT04298008 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-04-19

No results posted yet for this study

Summary

This trial will enroll advanced biliary tract cancer patients who have been previously treated with immunotherapy in either the 2nd or 3rd line.

Patients will be treated with AZD6738 and Durvalumab combination.

Conditions

Interventions

DRUG

AZD6738

AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks

DRUG

Durvalumab

Durvalumab 1500 mg iv on D1 Every 4 weeks

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-25
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04298008 on ClinicalTrials.gov